Burleson & Co’s Biogen BIIB Stock Holding History

Burleson & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$150K	Hold	540	–	–	0.04%	133
2022 Q3	$144K	Sell	540 -14	-3%	-$2.97K	0.03%	149
2022 Q2	$113K	Buy	554 +14	+3%	+$2.86K	0.02%	150
2022 Q1	$114K	Hold	540	–	–	0.02%	165
2021 Q4	$130K	Hold	540	–	–	0.02%	161
2021 Q3	$153K	Hold	540	–	–	0.02%	144
2021 Q2	$187K	Hold	540	–	–	0.03%	140
2021 Q1	$151K	Buy	+540	New	+$146K	0.02%	142

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Burleson & Co's BIIB Position: Q4 2022 in Review

Burleson & Co held its Biogen (BIIB) position steady in Q4 2022 at 540 shares worth $150K. The position accounts for 0.04% of the portfolio, ranked #133.

Burleson & Co first reported a position in BIIB in Q1 2021 and has held it in 8 quarters since. The position peaked at $187K in Q2 2021. 1,032 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Burleson & Co held 540 shares of Biogen worth $150K as of Q4 2022.
Burleson & Co left its Biogen share count unchanged in Q4 2022.
Biogen made up 0.04% of Burleson & Co's portfolio in Q4 2022, its #133 holding.
Burleson & Co first reported a position in Biogen in Q1 2021 and has held it in 8 quarters since.
Burleson & Co's Biogen position peaked at $187K in Q2 2021.
1,032 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.